The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Launched by GINKGO LEAF CENTER FOR RARE DISORDERS · May 16, 2017

Keywords

ClinConnect Summary

This clinical trial, called "The Longitudinal Approach to Acromegaly," is studying how patients with acromegaly are treated and how effective those treatments are over time in China. Acromegaly is a condition usually caused by a tumor on the pituitary gland, leading to excessive growth hormone in the body. The trial is currently looking for participants aged 18 to 75 who have been diagnosed with acromegaly, confirmed by specific blood tests and imaging showing a pituitary tumor.

Participants in this study will not be given any specific treatment but will be observed over time to gather information about their treatment patterns and health outcomes. To join, individuals must be able to provide informed consent and meet certain health criteria; for example, they should not have other serious health conditions or types of cancer that could affect the study. This research aims to improve understanding of acromegaly treatment and its effectiveness, which could ultimately lead to better care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Be able and willing to sign the informed consent form (ICF)
• • 2. Male, female, age 18-75 years old (including 18 years old and 75 years old).
• 3. Compliance with acromegaly diagnostic criteria:
• • At least one laboratory or medical record shows that the patient is random GH ≥ 2.5 μg / L
• • At least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor
• Exclusion Criteria:
• • 1. Ectopic secretion of GH or pituitary cancer
• • 2. The patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue.
• • 3. Have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study.
• • 4. Be a patient who, in the judgement of the Investigator, would be inappropriate for enrollment in this study